What versions of bosutinib/bosutinib are there?

Bosutinib/Bosutinib is a targeted drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Because of its important role in treatment, there are multiple versions of bosutinib on the market, including originator and generic versions.

The original drug of bosutinib is produced by Pfizer (Pfizer) and is mainly sold under the brand name "bosutinib". Pfizer's bosutinib is generally available in different dosage strengths, such as 400 mg and 500 mg. These original drugs have undergone rigorous clinical trials to verify their efficacy and safety, and are therefore widely recognized for use. When patients receive treatment, doctors will adjust the dosage and develop a personalized treatment plan based on their specific condition and tolerance.

In addition to the original drug, a number of generic drugs of bosutinib have also emerged on the international market. These generic drugs are mainly produced by pharmaceutical companies in India and some other countries, such as Mylan (Mylan). These generic drugs usually have the same active ingredients and therapeutic effects as the brand-name drugs, but are more cost-effective. For example, a generic version of bosutinib manufactured in India may be available to patients at a lower cost, helping them reduce their financial burden. Common generic drug strengths include 100 mg, 400 mg and 500 mg tablets, with specific dosage selection based on patient needs.

It is worth noting that although generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, due to differences in production processes and quality control, patients still need to choose carefully when using them, preferably under the guidance of a doctor. At the same time, some non-compliant drugs have also appeared on the market. Patients must go through formal channels when purchasing to ensure the quality and safety of the drugs.

Reference: https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif